Table 3.

Metaregression of included studies

Study characteristics	Prevalence of high risk (%, 95% CI)	P value	Prevalence of moderate risk (%, 95% CI)	P value
All studies	13.8 (10.9,16.8)		19.9 (16.8,23.1)
Sample type
Population survey	13.5 (8.8,18.1)	0.86	18.7 (14.3,23.1)	0.47
Community sample	14.0 (10.2,17.8)		21.0 (16.7,25.2)
Type of PEDS
Survey PEDS	17.9 (10.9,24.9)	0.15	20.6 (16.9,24.3)	0.50
Clinical PEDS	12.6(9.6,15.7)		18.3 (12.9,23.7)
Study purpose
Population risk measure	14.5 (9.7,19.2)	0.71	20.1 (15.4,24.9)	0.92
Developmental surveillance tool	13.3 (9.6,17.1)		19.8 (15.6,24.0)
Study quality
High quality	13.5 (8.8,18.1)	0.86	18.7 (14.3,23.1)	0.47
Medium/low quality	14.0 (10.2,17.8)		21.0 (16.7,25.2)
Study age group
3 years and under	14.5(8.9,20.2)	0.76	22.9(16.7,29.1)	0.25
Includes over 3 years	13.5(10.1,16.9)		18.9 (15.4,22.3)
Publication type
Peer review/Government report	11(8.1,14.0)	0.013	21.1(16.9,24.4)	0.39
Abstracts/website/manuals	18.0(13.0,22.9)		18.4(14.1,22.8)
Country income	High
High	13.2(10.2,16.3)	0.38	21.5(18.6,24.5)	0.001
Middle/low	17.2(8.2,26.1)		8.4(3.7,13.1)